Literature DB >> 34552675

Navigating the complex realm of drug access in paediatric care.

Paige H Dean1, Roxane Carr2, Chris Jensen3, Caron Strahlendorf1,4.   

Abstract

A Drug Access Navigator (DAN) is a role that has been established in patient care settings with the goal of expediting the process by which patients obtain drugs through the Health Canada Special Access Program (SAP), individual drug companies' patient access programs (PAP), and public and private drug plans. In the paediatric setting, the process of accessing many drugs has grown increasingly complex. The majority of paediatric prescriptions involve 'off-label' drug use. This leads to an increased need for drug access through the SAP and/or PAPs and demonstrates that the need for a DAN may be particularly prominent in the paediatric population. To our knowledge, there is no evidence in the literature of a DAN functioning in a paediatric setting, though there is a demonstrable need. We plan to address this need by introducing a DAN for shared use at BC Children's Hospital, a paediatric tertiary care centre.
© The Author(s) 2021. Published by Oxford University Press on behalf of the Canadian Paediatric Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Health economics; Oncology; Paediatrics; Patient care; Pharmacy

Year:  2021        PMID: 34552675      PMCID: PMC8448498          DOI: 10.1093/pch/pxab001

Source DB:  PubMed          Journal:  Paediatr Child Health        ISSN: 1205-7088            Impact factor:   2.253


  5 in total

1.  Physician perspectives on compassionate use in pediatric oncology.

Authors:  Scott Moerdler; Lindy Zhang; Elena Gerasimov; Chong Zhu; Tamar Wolinsky; Michael Roth; Nancy Goodman; Daniel A Weiser
Journal:  Pediatr Blood Cancer       Date:  2018-11-08       Impact factor: 3.167

Review 2.  Improving paediatric medications: A prescription for Canadian children and youth.

Authors:  Charlotte Moore Hepburn; Andrea Gilpin; Julie Autmizguine; Avram Denburg; L Lee Dupuis; Yaron Finkelstein; Emily Gruenwoldt; Shinya Ito; Geert 't Jong; Thierry Lacaze-Masmonteil; Deborah Levy; Stuart Macleod; Steven P Miller; Martin Offringa; Maury Pinsk; Barry Power; Michael Rieder; Catherine Litalien
Journal:  Paediatr Child Health       Date:  2019-07-25       Impact factor: 2.253

3.  Improving medicines for children in Canada. Findings of the expert panel on therapeutic products for infants, children and youth.

Authors:  Gideon Koren
Journal:  J Popul Ther Clin Pharmacol       Date:  2013-12-01

4.  Access to investigational medicinal products for minors in Europe: ethical and regulatory issues in negotiating children's access to investigational medicines.

Authors:  Wim Pinxten; Herman Nys; Kris Dierickx
Journal:  J Med Ethics       Date:  2010-09-18       Impact factor: 2.903

Review 5.  Pharmacare in Canada: The paediatric perspective.

Authors:  Tom McLaughlin; Geert 't Jong; Andrea Gilpin; Charlotte Moore Hepburn
Journal:  Paediatr Child Health       Date:  2020-03-13       Impact factor: 2.253

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.